nuMoM2b Fetal Adrenal Gland Ultrasound Visit 3 [U3D] Dataset in Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be

Data from Fetal Adrenal Gland Measures Visit 3 [U3D] form completed for a subset of participants between 22-29 weeks project estimated gestational age and at least 4 weeks after the Visit 2 fetal biometry only if the participant met the inclusion and exclusion criteria for the Ancillary Fetal Adrenal Gland Study and agreed to the measurement
Study Description
NuMoM2b studied underlying, interrelated, mechanisms of adverse pregnancy outcomes (e.g., preterm birth, preeclampsia, fetal growth restriction) in pregnant women with no previous pregnancy lasting 20 weeks-0 days or more estimated gestational age (nulliparas). The network included 8 clinical sites, subsites, NICHD, and a data center. Women enrolled early in pregnancy and were followed through delivery, with study visits at 6 weeks-0 days to 13 weeks-6 days, 16 weeks-0 days to 21 weeks-6 days, 22 weeks-0 days to 29 weeks-6 days gestation, and delivery. Data collected through interviews, self-administered questionnaires, clinical measurements, ultrasounds, and medical records review included demographic, psychosocial, dietary, physiologic, health, and pregnancy outcome information. Subsets of participants enrolled in sleep disordered breathing, sleep patterns and quality, and fetal adrenal gland substudies. Pregnant women with no previous pregnancy lasting =20 weeks estimated gestational age (nulliparas); although 10,038 women enrolled in the study, during consent, only 9,289 of these women agreed to release their data into shared databases maintained by NIH